54015-04-2

Usage

Uses

Used in Rubber Industry:
N-P-Tolyl-guanidine is used as a rubber accelerator and antioxidant for improving the tensile and fatigue properties of rubber. This makes it an essential component in the production of tires, conveyor belts, and other rubber products, ensuring their durability and performance.
Used in Pharmaceutical and Organic Chemical Synthesis:
N-P-Tolyl-guanidine is used as an intermediate in the synthesis of various pharmaceuticals and organic chemicals. Its role in these processes is crucial for the development of new compounds and formulations.
Safety Precautions:
While N-P-Tolyl-guanidine offers significant benefits in its applications, it should be handled with care. It may cause skin and eye irritation, and can be harmful if ingested or inhaled. Proper safety measures should be taken during its use to minimize potential health risks.

Upstream product

• 420-04-2 CYANAMID 
• 106-49-0 p-toluidine 
• 97730-69-3 p-tolylguanidine carbonate 
• 32954-54-4 para-methyl anilinium nitrate 
• 540-23-8 p-toluidine hydrochloride 

Downstream Products

• 102157-82-4 p-tolylcarbamimidoyl-amidophosphoric acid diphenyl ester 
• 52541-50-1 4-(4-methyl-anilino)-3H-[1,3,5]thiadiazine-2,6-dithione 
• 14294-04-3 N-(p-Tolylcarbamimidoyl)-N'-(tert.-butyl)-thioharnstoff 
• 170747-18-9 N-(6-chloro-1,1-dioxo-7-methyl-1,4,2-benzodithiazin-3-yl)-N'-(p-tolyl)guanidine 
• 170747-24-7 N-(6-chloro-1,1-dioxo-7-methoxycarbonyl-1,4,2-benzodithiazin-3-yl)-N'-(p-tolyl)guanidine 
• 1126642-78-1 3,5,6-trimethyl-N-(N-p-tolylcarbamimidoyl)pyrazine-2-carboxamide 
• 1415509-19-1 C₁₉H₁₇N₅ 
• 1610885-99-8 3,4-dimethyl-5-(2-(p-tolylamino)pyrimidin-4-yl)thiazol-2(3H)-one 
• 96717-15-6 4,6-Bis-(4-fluorphenyl)-2-(4-toluidino)pyrimidin 
• 96717-14-5 4-Trifluormethyl-6-(2-naphtyl)-2-(4-toluidino)pyrimidin 

Relevant academic research and scientific papers

Discovery of CDK5 Inhibitors through Structure-Guided Approach

Specific abrogation of cyclin-dependent kinase 5 (CDK5) activity has been validated as a viable approach for the development of anticancer agents. However, no selective CDK5 inhibitor has been reported to date. Herein, a structure-based in silico screenin

Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors

CDK4/6 pathway is an attractive target for development of anti-cancer drugs. Herein, we reported the design and synthesis of a series of 4,5-dihydro-1H-pyrazolo [4,3-h]quinazoline derivatives as selective CDK4/6 inhibitors. Applied with the optimizing strategy to the initial scaffold, it is found that compound 13n is able to selectively inhibit CDK4 and CDK6 with IC50 values 0.01 and 0.026 μM, respectively. The compound showed good anti-proliferative activity when tested in a panel of tumor cell lines with CDK4/6 related mechanism of action, the results clearly suggest that compound 13n works much better than Ly2385219 which is a selective CDK4/6 inhibitor. This compound was also found to have favorable pharmacokinetic parameters. Taken together, compound 13n could be selected for further preclinical evaluation.

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: Synthesis, SAR analysis and biological evaluation

Phosphorylation of eIF4E by human mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) is crucial for human tumourigenesis and development. Targeting Mnks may provide a novel anticancer therapeutic strategy. However, the lack of selective Mnk inhibitors has so far hampered pharmacological target validation and clinical drug development. Herein, we report, for the first time, the discovery of a series of 5-(2-(phenylamino) pyrimidin-4-yl)thiazole-2(3H)-one derivatives as Mnk inhibitors. Several derivatives demonstrate very potent Mnk2 inhibitory activity. The most active and selective compounds were tested against a panel of cancer cell lines, and the results confirm the cell-type-specific effect of these Mnk inhibitors. Detailed cellular mechanistic studies reveal that Mnk inhibitors are capable of reducing the expression level of anti-apoptotic protein Mcl-1, and of promoting apoptosis in MV4-11 acute myeloid leukaemia cells. Highly active Mnk2 inhibitors: Mnk-related cancer biology is an area of intensive research, but its inhibitor discovery has lagged behind due to a lack of understanding of the protein structure. Herein we report the discovery of Mnk2 inhibitors (e.g. 8 e). These potent and selective inhibitors are extremely valuable for target validation and drug discovery.

Reaction of quinones and guanidine derivatives: Simple access to bis-2-aminobenzimidazole moiety of benzosceptrin and other benzazole motifs

A new strategy for the synthesis of 2-aminobenzimidazol-6-ols via a reaction of quinones with guanidine derivatives is reported. Sequential application of this methodology provided a simple access to the first benzosceptrin analogue bearing a bis-2-aminoimidazole moiety. A concomitant addition of two guanidines to the naphtho[1′,2′:4,5]imidazo[1,2-a] pyrimidine-5,6-dione, which includes the redox neutral debenzylation and guanidine-assisted cleavage of the 2-aminopyrimidine part resulted in the synthesis of the free challenging contiguous bis-2-aminoimidazole moiety of benzosceprins in one step.

Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents

A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.